Pancreatic Cancer Research

ResearcherMedical College of WisconsinNo recent work listed

Parag P. Tolat

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-1260-5456; OpenAlex author ID A5016194461. Sources: OpenAlex.

Their work

Papers
20 (first author 1, last author 2)
Trials
0
Grants
0
Labs led
1
Collaborators
53
Papers, trials and grants by year

2012: 1 paper · 2013: 1 paper · 2014: 2 papers · 2015: 1 paper · 2016: 4 papers · 2017: none · 2018: 3 papers · 2019: 1 paper · 2020: 3 papers · 2021: 1 paper · 2022: none · 2023: 3 papers

Papers 20

  1. Postoperative surveillance of pancreatic ductal adenocarcinoma (PDAC) recurrence: practice pattern on standardized imaging and reporting from the society of ab… Co-author DOI 10.1007/s00261-022-03693-0↗
  2. Determination of "borderline resectable" pancreatic cancer - A global assessment of 30 shades of grey. Co-author DOI 10.1016/j.hpb.2023.07.883↗
  3. CA19-9 Response to First-Line Neoadjuvant FOLFIRINOX and Second-Line Gemcitabine/Nab-Paclitaxel for Patients with Operable Pancreatic Cancer. Co-author DOI 10.1245/s10434-022-13055-1↗
  4. Multimodality Imaging for the Staging of Pancreatic Cancer. Last author DOI 10.1016/j.soc.2021.06.006↗
  5. White paper on pancreatic ductal adenocarcinoma from society of abdominal radiology's disease-focused panel for pancreatic ductal adenocarcinoma: Part I, AJCC … Co-author DOI 10.1007/s00261-019-02289-5↗
  6. White paper on pancreatic ductal adenocarcinoma from society of abdominal radiology's disease-focused panel for pancreatic ductal adenocarcinoma: Part II, upda… Co-author DOI 10.1007/s00261-019-02290-y↗
  7. Value of Pretreatment 18F-fluorodeoxyglucose Positron Emission Tomography in Patients With Localized Pancreatic Cancer Treated With Neoadjuvant Therapy. Co-author DOI 10.3389/fonc.2020.00500↗
  8. Survival of patients with borderline resectable pancreatic cancer who received neoadjuvant therapy and surgery. Co-author DOI 10.1016/j.surg.2019.05.010↗
  9. Pancreatic adenocarcinoma: cross-sectional imaging techniques. Co-author DOI 10.1007/s00261-017-1380-4↗
  10. Characterizing indeterminate liver lesions in patients with localized pancreatic cancer at the time of diagnosis. Last author DOI 10.1007/s00261-017-1404-0↗
  11. A Phase II Clinical Trial of Molecular Profiled Neoadjuvant Therapy for Localized Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1097/sla.0000000000002957↗
  12. Neoadjuvant treatment sequencing adds value to the care of patients with operable pancreatic cancer. Co-author DOI 10.1002/jso.24316↗
  13. Venous thromboembolism prophylaxis during neoadjuvant therapy for resectable and borderline resectable pancreatic cancer-Is it indicated? Co-author DOI 10.1002/jso.24361↗
  14. Survival of patients with resectable pancreatic cancer who received neoadjuvant therapy. Co-author DOI 10.1016/j.surg.2015.09.018↗
  15. Evolution of the Management of Resectable Pancreatic Cancer. Co-author DOI 10.1200/jop.2016.015818↗
  16. Neoadjuvant therapy for localized pancreatic cancer: guiding principles. Co-author DOI 10.3978/j.issn.2078-6891.2015.053↗
  17. Optimal management of the splenic vein at the time of venous resection for pancreatic cancer: importance of the inferior mesenteric vein. Co-author DOI 10.1007/s11605-013-2428-6↗
  18. Staging chest computed tomography and positron emission tomography in patients with pancreatic adenocarcinoma: utility or futility? Co-author DOI 10.1111/hpb.12074↗
  19. Critical steps for pancreaticoduodenectomy in the setting of pancreatic adenocarcinoma. Co-author DOI 10.1002/jso.23166↗
  20. Current staging systems for pancreatic cancer. First author DOI 10.1097/ppo.0b013e318278c5b5↗

Closest collaborators

The 25 strongest of 53 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Douglas B. Evans · 14 shared papers, 2012–2023 · strength 0.99
  2. Susan Tsai · 14 shared papers, 2012–2023 · strength 0.99
  3. Kathleen K. Christians · 11 shared papers, 2013–2023 · strength 0.81
  4. Bradley A. Erickson · 10 shared papers, 2014–2023 · strength 0.77
  5. Ben George · 7 shared papers, 2015–2023 · strength 0.59
  6. Paul S. Ritch · 8 shared papers, 2014–2020 · strength 0.53
  7. Naveen M. Kulkarni · 5 shared papers, 2018–2023 · strength 0.50
  8. Mohammed Aldakkak · 4 shared papers, 2018–2023 · strength 0.43
  9. William Adrian Hall · 4 shared papers, 2018–2023 · strength 0.42
  10. Erik V. Soloff · 4 shared papers, 2018–2023 · strength 0.42
  11. Avinash R. Kambadakone · 4 shared papers, 2018–2023 · strength 0.42
  12. Callisia Nathelee Clarke · 3 shared papers, 2019–2023 · strength 0.35
  13. Zhen J. Wang · 3 shared papers, 2020–2023 · strength 0.31
  14. Marc Zins · 3 shared papers, 2020–2023 · strength 0.31
  15. Eric Peter Tamm · 3 shared papers, 2020–2023 · strength 0.31
  16. Olga Rachel Brook · 3 shared papers, 2020–2023 · strength 0.31
  17. Lorenzo Mannelli · 3 shared papers, 2020–2023 · strength 0.31
  18. Priya Bhosale · 3 shared papers, 2020–2023 · strength 0.31
  19. Elizabeth M. Hecht · 3 shared papers, 2020–2023 · strength 0.31
  20. Kulwinder S. Dua · 3 shared papers, 2016–2019 · strength 0.23
  21. Martin McKinney · 1 shared paper, 2021 · strength 0.22
  22. Jason B. Fleming · 2 shared papers, 2020 · strength 0.19
  23. Chad A. Barnes · 2 shared papers, 2019–2020 · strength 0.18
  24. Sam Z. Thalji · 1 shared paper, 2023 · strength 0.17
  25. Mandana Kamgar · 1 shared paper, 2023 · strength 0.17

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.